Opportunity Information: Apply for PA 12 213
Apply for PA 12 213
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Identifying Non coding RNA Targets for Early Detection of Cancer (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Jun 19, 2012 and posted on Jun 19, 2012.
- Applicants must submit their applications by Sep 7, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: For profit organizations other than small businesses Special district governments Small businesses Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public housing authorities/Indian housing authorities County governments Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Identifying Non-coding RNA Targets for Early Detection of Cancer (R01)" (Funding Opportunity Number PA-12-213) is a National Cancer Institute (NCI) Funding Opportunity Announcement that supports investigator-initiated research using the NIH R01 grant mechanism. Its central goal is to advance both basic and translational research on non-coding RNAs (ncRNAs) in the earliest phases of cancer, with a strong emphasis on understanding how ncRNAs and their molecular targets function in preneoplastic lesions and early-stage tumors. The announcement is positioned to build on prior progress in microRNA (miRNA) biology and biomarker development, while explicitly expanding attention to all classes of ncRNAs, not only miRNAs.
Scientifically, the FOA encourages projects that identify and characterize ncRNAs that are involved in the transition from normal tissue to premalignant change and then to early malignancy. A key theme is uncovering ncRNA targets and pathways that could explain early tumor initiation, early clonal evolution, or early microenvironmental changes, since these are the biological windows where detection and prevention can have the greatest impact. The announcement also highlights the potential value of "stable" miRNAs and other ncRNAs, which can persist in clinical specimens and biofluids, making them more practical for real-world testing. In addition to mechanistic work, the FOA encourages biomarker-focused studies that evaluate whether specific ncRNAs can predict which preneoplastic lesions are likely to progress to invasive cancer, and whether ncRNA signatures can be used for early detection or screening.
From a translation standpoint, the opportunity is meant to push the field beyond discovery and toward clinically useful applications. That includes research aimed at assessing performance characteristics relevant to screening and diagnosis, such as whether ncRNA-based markers can reliably distinguish benign, premalignant, and malignant states; whether they can detect cancers at an earlier and more treatable stage; and whether they can stratify risk among patients with known premalignant conditions. The FOA specifically states an interest in supporting efforts that move stable miRNAs toward cancer screening or diagnostic tests, which signals that proposals can include steps along the pathway from biomarker identification to assay development and validation, as long as the work remains within the scope of an R01 research project.
Administratively, this is a discretionary grant program under the National Institutes of Health, with activity areas aligned to cancer cause and prevention research (93.393), cancer detection and diagnosis research (93.394), and cancer treatment research (93.395). There is no cost sharing or matching requirement. The program was posted on June 19, 2012, and the original and final closing date listed is September 7, 2015, with an archive date of October 8, 2015, indicating that the specific FOA is no longer open but remains as a reference point for the kinds of projects NCI sought to fund in this area.
Eligibility is broad and includes many organizational types: public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), and a range of government entities (state, county, city/township, special district governments, and public housing authorities/Indian housing authorities). The FOA also lists several additional eligible applicant categories such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations), among others. This wide eligibility reflects an intent to attract multidisciplinary teams spanning molecular biology, genomics, biomarker science, clinical oncology, pathology, and technology development.
For applicants seeking the full archived announcement and official details, the FOA link provided is http://grants.nih.gov/grants/guide/pa-files/PA-12-213.html, and NIH Office of Extramural Research (OER) contact support is available through the OER Webmaster at FBOWebmaster@OD.NIH.GOV for access or linking issues.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "Identifying Non-coding RNA Targets for Early Detection of Cancer (R01)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PA-12-213.
Which agency and institute offered this opportunity?
This is a National Institutes of Health (NIH) Funding Opportunity Announcement administered by the National Cancer Institute (NCI).
What grant mechanism does this FOA use?
This FOA supports investigator-initiated research using the NIH R01 grant mechanism.
What is the central goal of this FOA?
The central goal is to advance basic and translational research on non-coding RNAs (ncRNAs) in the earliest phases of cancer, with an emphasis on understanding how ncRNAs and their molecular targets function in preneoplastic lesions and early-stage tumors.
Is the focus limited to microRNAs (miRNAs)?
No. While it builds on prior progress in microRNA (miRNA) biology and biomarker development, the FOA explicitly expands attention to all classes of non-coding RNAs (ncRNAs), not only miRNAs.
What stages of cancer development are emphasized?
The FOA emphasizes the earliest phases of cancer development, including the transition from normal tissue to premalignant change (preneoplastic lesions) and then to early malignancy (early-stage tumors).
What kinds of scientific questions or themes does the FOA encourage?
The FOA encourages projects that identify and characterize ncRNAs involved in early cancer development, including work that uncovers ncRNA targets and pathways relevant to early tumor initiation, early clonal evolution, and early microenvironmental changes.
Does the FOA encourage mechanistic (basic biology) research?
Yes. A major emphasis is understanding how ncRNAs and their molecular targets function in preneoplastic lesions and early-stage tumors, which includes mechanistic work.
Does the FOA encourage translational and biomarker-related research?
Yes. In addition to mechanistic studies, the FOA encourages biomarker-focused research evaluating whether specific ncRNAs can be used for early detection or screening, including predicting which preneoplastic lesions are likely to progress to invasive cancer.
What does the FOA mean by "stable" miRNAs and other stable ncRNAs?
The FOA highlights the value of ncRNAs (including miRNAs) that are "stable" in the sense that they can persist in clinical specimens and biofluids, making them more practical for real-world testing.
What kinds of clinical performance questions are of interest for ncRNA biomarkers?
The FOA notes interest in performance characteristics relevant to screening and diagnosis, such as whether ncRNA-based markers can reliably distinguish benign, premalignant, and malignant states; detect cancers at an earlier and more treatable stage; and stratify risk among patients with known premalignant conditions.
Is assay development and validation within scope?
The FOA signals that proposals may include steps along the pathway from biomarker identification to assay development and validation, as long as the work remains within the scope of an R01 research project.
What is the overall translational intent of the announcement?
The FOA is intended to push the field beyond discovery and toward clinically useful applications, including moving stable miRNAs and other ncRNAs toward cancer screening or diagnostic tests.
What types of research areas does this program align with (CFDA/assistance areas)?
The activity areas listed are cancer cause and prevention research (93.393), cancer detection and diagnosis research (93.394), and cancer treatment research (93.395).
Is this a discretionary grant program?
Yes. The FOA is described as a discretionary grant program under NIH.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
When was this FOA posted?
The program was posted on June 19, 2012.
What were the closing dates for applications?
The original and final closing date listed is September 7, 2015.
Is this FOA still open for applications?
No. The archive date is October 8, 2015, indicating the specific FOA is no longer open and remains as a reference for the types of projects NCI sought to fund in this area.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (including small businesses and other for-profits); and government entities such as state, county, city/township, special district governments, and public housing authorities/Indian housing authorities.
Are minority-serving institutions specifically included as eligible applicants?
Yes. The FOA lists categories such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, and tribally controlled colleges and universities (TCCUs), among others.
Are Alaska Native, Native Hawaiian, and other serving institutions included?
Yes. The FOA includes Alaska Native and Native Hawaiian serving institutions among eligible applicant categories.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are listed among eligible applicant categories.
Are U.S. territories or possessions and regional organizations eligible?
Yes. The FOA lists U.S. territories or possessions and regional organizations among eligible applicant categories.
Are non-U.S. entities eligible to apply?
Yes. The FOA indicates that non-U.S. entities (foreign organizations) are included among eligible applicants.
What kinds of teams or disciplines does the broad eligibility aim to attract?
The FOA reflects an intent to attract multidisciplinary teams spanning molecular biology, genomics, biomarker science, clinical oncology, pathology, and technology development.
Where can applicants find the full archived FOA text?
The FOA link provided is: http://grants.nih.gov/grants/guide/pa-files/PA-12-213.html
Who should be contacted for help accessing the FOA link or for linking issues?
NIH Office of Extramural Research (OER) contact support is available through the OER Webmaster at FBOWebmaster@OD.NIH.GOV for access or linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Identifying Non coding RNA Targets for Early Detection of Cancer (R21)
Previous opportunity: Affordable Care Act Maternal, Infant and Early Childhood Home Visiting Program Grants to Nonprofit Organizations
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 213
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 213) also looked into and applied for these:
| Funding Opportunity |
|---|
| Identifying Non coding RNA Targets for Early Detection of Cancer (R21) Apply for PA 12 214 Funding Number: PA 12 214 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 12 220 Funding Number: PA 12 220 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 12 221 Funding Number: PA 12 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cohort Studies of HIV/AIDS and Substance Use (U01) Apply for PAR 12 222 Funding Number: PAR 12 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R01) Apply for RFA MH 13 090 Funding Number: RFA MH 13 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R21) Apply for RFA MH 13 091 Funding Number: RFA MH 13 091 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R34) Apply for RFA MH 13 092 Funding Number: RFA MH 13 092 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Addressing Needs of Informal Caregivers of Individuals with Alzheimers Disease in the Context of Sociodemographic Factors (R01) Apply for RFA NR 13 001 Funding Number: RFA NR 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R01) Apply for PAR 12 228 Funding Number: PAR 12 228 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R21) Apply for PAR 12 229 Funding Number: PAR 12 229 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research on Interventions for Adolescents in the Legal System TRIALS (U01) Apply for RFA DA 13 009 Funding Number: RFA DA 13 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PAR 12 238 Funding Number: PAR 12 238 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Clinical Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PAR 12 239 Funding Number: PAR 12 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| NCI National Clinical Trials Network Network Radiotherapy and Imaging Core Services Centers (U24) Apply for RFA CA 12 014 Funding Number: RFA CA 12 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Canadian Collaborating Clinical Trials Network (Limited Competition U10) Apply for RFA CA 12 504 Funding Number: RFA CA 12 504 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Operations Centers (U10) Apply for RFA CA 12 010 Funding Number: RFA CA 12 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Statistics and Data Management Centers (U10) Apply for RFA CA 12 011 Funding Number: RFA CA 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Integrated Translational Science Centers (U10) Apply for RFA CA 12 012 Funding Number: RFA CA 12 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Lead Academic Participating Sites (U10) Apply for RFA CA 12 013 Funding Number: RFA CA 12 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 12 251 Funding Number: PAR 12 251 Agency: National Institutes of Health Category: Education Health Funding Amount: $75,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 213", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.